AAPL311.74-4.49 (-1.42%) ▼|ABBV249.21+0.43 (+0.17%) ▲|ABT106.46+0.94 (+0.89%) ▲|ACN177.09-1.94 (-1.08%) ▼|ADBE255.63-1.63 (-0.63%) ▼|AMAT465.86-6.93 (-1.47%) ▼|AMD519.99+14.25 (+2.82%) ▲|AMGN392.89-0.29 (-0.07%) ▼|AMT174.71-1.02 (-0.58%) ▼|AMZN251.02-5.95 (-2.32%) ▼|AVGO361.15-7.42 (-2.01%) ▼|AXP322.16-3.94 (-1.21%) ▼|BA209.94-0.79 (-0.37%) ▼|BAC62.77+0.38 (+0.61%) ▲|BKNG172.08-8.22 (-4.56%) ▼|BLK1,079.45-15.92 (-1.45%) ▼|BMY64.41-0.29 (-0.44%) ▼|BNY162.76-0.09 (-0.06%) ▼|BRK-B506.51+0.68 (+0.13%) ▲|C137.89+1.15 (+0.84%) ▲|CAT814.02-8.46 (-1.03%) ▼|CL88.12-0.29 (-0.33%) ▼|CMCSA24.95-1.39 (-5.26%) ▼|COF212.11-1.85 (-0.86%) ▼|COP137.45+2.41 (+1.78%) ▲|COST901.32-8.86 (-0.97%) ▼|CRM249.26+0.14 (+0.05%) ▲|CSCO109.50+0.33 (+0.30%) ▲|CVS95.20-0.87 (-0.91%) ▼|CVX213.22+3.42 (+1.63%) ▲|DE674.49-6.25 (-0.92%) ▼|DHR204.83-0.40 (-0.19%) ▼|DIS104.61-0.45 (-0.43%) ▼|DUK119.88-1.36 (-1.12%) ▼|EMR151.56-0.59 (-0.39%) ▼|FDX310.38-3.75 (-1.19%) ▼|GD353.17-3.41 (-0.96%) ▼|GE323.84-11.07 (-3.31%) ▼|GEV949.41-21.90 (-2.25%) ▼|GILD146.32-0.33 (-0.22%) ▼|GM85.58-0.21 (-0.24%) ▼|GOOG326.97-8.41 (-2.51%) ▼|GOOGL329.44-8.92 (-2.64%) ▼|GS1,027.30-9.24 (-0.89%) ▼|HD311.34-2.37 (-0.75%) ▼|HON205.90-2.34 (-1.12%) ▼|IBM231.14-0.96 (-0.41%) ▼|INTC105.28+0.81 (+0.78%) ▲|INTU315.60-3.33 (-1.04%) ▼|ISRG351.24+1.08 (+0.31%) ▲|JNJ268.77-0.35 (-0.13%) ▼|JPM354.74+1.23 (+0.35%) ▲|KO87.88-0.48 (-0.54%) ▼|LIN464.75-3.64 (-0.78%) ▼|LLY1,128.30+4.39 (+0.39%) ▲|LMT527.30-8.86 (-1.65%) ▼|LOW198.55-2.25 (-1.12%) ▼|LRCX314.07-6.36 (-1.98%) ▼|MA566.33-4.56 (-0.80%) ▼|MCD253.65-2.16 (-0.84%) ▼|MDLZ61.67+0.04 (+0.06%) ▲|MDT92.55+0.16 (+0.17%) ▲|META654.35+40.87 (+6.66%) ▲|MMM165.26-2.26 (-1.35%) ▼|MO67.55-0.62 (-0.91%) ▼|MRK147.48-0.99 (-0.66%) ▼|MS215.27-0.97 (-0.45%) ▼|MSFT492.33-1.62 (-0.33%) ▼|MU1,024.73+24.47 (+2.45%) ▲|NEE82.72-1.11 (-1.32%) ▼|NFLX76.53-0.25 (-0.32%) ▼|NKE37.17-0.93 (-2.44%) ▼|NOW132.52-1.69 (-1.26%) ▼|NVDA224.25-1.49 (-0.66%) ▼|ORCL161.45-1.07 (-0.66%) ▼|PEP136.55-1.90 (-1.37%) ▼|PFE27.91+0.12 (+0.41%) ▲|PG142.84-2.74 (-1.88%) ▼|PLTR171.08+0.78 (+0.46%) ▲|PM183.74-0.99 (-0.54%) ▼|QCOM175.33+1.24 (+0.71%) ▲|RTX198.72-0.09 (-0.05%) ▼|SBUX100.09-1.92 (-1.88%) ▼|SCHW107.54+0.67 (+0.63%) ▲|SO88.25-0.75 (-0.84%) ▼|SPG207.46-2.17 (-1.04%) ▼|T24.98-0.62 (-2.42%) ▼|TMO606.72+3.70 (+0.61%) ▲|TMUS177.44-4.25 (-2.34%) ▼|TSLA369.42+1.26 (+0.34%) ▲|TXN260.57+1.65 (+0.64%) ▲|UBER71.37-1.77 (-2.41%) ▼|UNH390.37-10.47 (-2.61%) ▼|UNP285.44-3.02 (-1.05%) ▼|UPS99.78-0.70 (-0.70%) ▼|USB62.27-0.22 (-0.35%) ▼|V367.01-1.63 (-0.44%) ▼|VZ49.32-1.10 (-2.17%) ▼|WFC89.38+1.42 (+1.61%) ▲|WMT105.84-0.22 (-0.20%) ▼|XOM163.60+2.94 (+1.83%) ▲|AAPL311.74-4.49 (-1.42%) ▼|ABBV249.21+0.43 (+0.17%) ▲|ABT106.46+0.94 (+0.89%) ▲|ACN177.09-1.94 (-1.08%) ▼|ADBE255.63-1.63 (-0.63%) ▼|AMAT465.86-6.93 (-1.47%) ▼|AMD519.99+14.25 (+2.82%) ▲|AMGN392.89-0.29 (-0.07%) ▼|AMT174.71-1.02 (-0.58%) ▼|AMZN251.02-5.95 (-2.32%) ▼|AVGO361.15-7.42 (-2.01%) ▼|AXP322.16-3.94 (-1.21%) ▼|BA209.94-0.79 (-0.37%) ▼|BAC62.77+0.38 (+0.61%) ▲|BKNG172.08-8.22 (-4.56%) ▼|BLK1,079.45-15.92 (-1.45%) ▼|BMY64.41-0.29 (-0.44%) ▼|BNY162.76-0.09 (-0.06%) ▼|BRK-B506.51+0.68 (+0.13%) ▲|C137.89+1.15 (+0.84%) ▲|CAT814.02-8.46 (-1.03%) ▼|CL88.12-0.29 (-0.33%) ▼|CMCSA24.95-1.39 (-5.26%) ▼|COF212.11-1.85 (-0.86%) ▼|COP137.45+2.41 (+1.78%) ▲|COST901.32-8.86 (-0.97%) ▼|CRM249.26+0.14 (+0.05%) ▲|CSCO109.50+0.33 (+0.30%) ▲|CVS95.20-0.87 (-0.91%) ▼|CVX213.22+3.42 (+1.63%) ▲|DE674.49-6.25 (-0.92%) ▼|DHR204.83-0.40 (-0.19%) ▼|DIS104.61-0.45 (-0.43%) ▼|DUK119.88-1.36 (-1.12%) ▼|EMR151.56-0.59 (-0.39%) ▼|FDX310.38-3.75 (-1.19%) ▼|GD353.17-3.41 (-0.96%) ▼|GE323.84-11.07 (-3.31%) ▼|GEV949.41-21.90 (-2.25%) ▼|GILD146.32-0.33 (-0.22%) ▼|GM85.58-0.21 (-0.24%) ▼|GOOG326.97-8.41 (-2.51%) ▼|GOOGL329.44-8.92 (-2.64%) ▼|GS1,027.30-9.24 (-0.89%) ▼|HD311.34-2.37 (-0.75%) ▼|HON205.90-2.34 (-1.12%) ▼|IBM231.14-0.96 (-0.41%) ▼|INTC105.28+0.81 (+0.78%) ▲|INTU315.60-3.33 (-1.04%) ▼|ISRG351.24+1.08 (+0.31%) ▲|JNJ268.77-0.35 (-0.13%) ▼|JPM354.74+1.23 (+0.35%) ▲|KO87.88-0.48 (-0.54%) ▼|LIN464.75-3.64 (-0.78%) ▼|LLY1,128.30+4.39 (+0.39%) ▲|LMT527.30-8.86 (-1.65%) ▼|LOW198.55-2.25 (-1.12%) ▼|LRCX314.07-6.36 (-1.98%) ▼|MA566.33-4.56 (-0.80%) ▼|MCD253.65-2.16 (-0.84%) ▼|MDLZ61.67+0.04 (+0.06%) ▲|MDT92.55+0.16 (+0.17%) ▲|META654.35+40.87 (+6.66%) ▲|MMM165.26-2.26 (-1.35%) ▼|MO67.55-0.62 (-0.91%) ▼|MRK147.48-0.99 (-0.66%) ▼|MS215.27-0.97 (-0.45%) ▼|MSFT492.33-1.62 (-0.33%) ▼|MU1,024.73+24.47 (+2.45%) ▲|NEE82.72-1.11 (-1.32%) ▼|NFLX76.53-0.25 (-0.32%) ▼|NKE37.17-0.93 (-2.44%) ▼|NOW132.52-1.69 (-1.26%) ▼|NVDA224.25-1.49 (-0.66%) ▼|ORCL161.45-1.07 (-0.66%) ▼|PEP136.55-1.90 (-1.37%) ▼|PFE27.91+0.12 (+0.41%) ▲|PG142.84-2.74 (-1.88%) ▼|PLTR171.08+0.78 (+0.46%) ▲|PM183.74-0.99 (-0.54%) ▼|QCOM175.33+1.24 (+0.71%) ▲|RTX198.72-0.09 (-0.05%) ▼|SBUX100.09-1.92 (-1.88%) ▼|SCHW107.54+0.67 (+0.63%) ▲|SO88.25-0.75 (-0.84%) ▼|SPG207.46-2.17 (-1.04%) ▼|T24.98-0.62 (-2.42%) ▼|TMO606.72+3.70 (+0.61%) ▲|TMUS177.44-4.25 (-2.34%) ▼|TSLA369.42+1.26 (+0.34%) ▲|TXN260.57+1.65 (+0.64%) ▲|UBER71.37-1.77 (-2.41%) ▼|UNH390.37-10.47 (-2.61%) ▼|UNP285.44-3.02 (-1.05%) ▼|UPS99.78-0.70 (-0.70%) ▼|USB62.27-0.22 (-0.35%) ▼|V367.01-1.63 (-0.44%) ▼|VZ49.32-1.10 (-2.17%) ▼|WFC89.38+1.42 (+1.61%) ▲|WMT105.84-0.22 (-0.20%) ▼|XOM163.60+2.94 (+1.83%) ▲|
27.1 C
New York
Wednesday, September 9, 2026

Tag: heart failure

newssourceFORcompanyinformationcontent1releasesmarket

Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction

SUNNYVALE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Henry Ford Health in Detroit, Michigan is now enrolling patients with ischemic HFrEF in the Company’s ongoing pivotal CardiAMP HF II trial.

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy...

FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.

Johnson & Johnson Launches VARIPULSE™ Platform across Asia-Pacific, Advancing Atrial Fibrillation Treatment

The VARIPULSE™ Platform is the first Pulsed Field Ablation (PFA) system fully integrated with the CARTO™ 3 electroanatomical mapping system, designed to drive efficiency,...

Simplex Quantum Welcomes Dr. Marco Perez as an Advisor to Advance AI-Driven Heart Failure Detection

TOKYO, July 7, 2025 /PRNewswire/ -- Simplex Quantum, an AI-driven healthcare technology company, is proud to announce that Dr. Marco Perez, Associate Professor of...

Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT

Nuevocor Strengthens Board with Appointment of Thierry Abribat

SINGAPORE, July 7, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced the appointment of Dr....

Public Advisory – NRA-Amlodipine 5 mg tablets: One lot recalled as some bottles may contain the wrong drug

OTTAWA, ON, July 5, 2025 /CNW/ - Summary Product: NRA-Amlodipine 5 mg, DIN 02476460Issue: Health products - Product safetyWhat to do: Check your bottle of NRA-Amlodipine 5 mg...

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

The sleep apnea market growth is driven by rising awareness, technological advancements, and demand for personalized care. Companies innovate therapies and solutions for better...

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.

Clover Health Set to Join Russell 3000® Index

WILMINGTON, Del., June 30, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), announced that it is set to join the broad-market Russell 3000® Index, effective after the US market opens today, June 30, 2025, as part of the 2025 Russell indexes reconstitution.

InterShunt Enrolls First Patient in New Heart Failure Study

Innovative procedure aims to ease symptoms and reduce hospitalizations MINNEAPOLIS, June 30, 2025 /PRNewswire/ -- InterShunt Technologies, Inc., a medical device company focused on...

Press release: Transparency Notification from Shareholders

Transparency Notification from Shareholders

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and...

Bagsværd, Denmark, 23 June 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic® (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.

Oral Semaglutide Significantly Improves Cardiovascular Outcomes in Individuals with Type 2 Diabetes

Oral formulation demonstrates comparable cardiovascular benefits to injectable GLP-1s CHICAGO, June 22, 2025 /PRNewswire/ -- A recent study found that oral semaglutide offers meaningful cardiovascular benefits...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsHeart failure

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers